Want to see ASMB full AI Analyst Report?
ASMB Stock Chart & Stats
$29.24
-$0.45(-2.59%)
At close: 4:00 PM EST
$29.24
-$0.45(-2.59%)
Day’s Range― - ―
52-Week Range$16.90 - $39.71
Previous CloseN/A
Volume7.37K
Average Volume (3M)164.41K
Market Cap
$531.30M
Enterprise Value$244.87
Total Cash (Recent Filing)$226.60M
Total Debt (Recent Filing)$2.49M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 12, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding19,817,250
10 Day Avg. Volume178,321
30 Day Avg. Volume164,409
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)1.84
Price to Sales (P/S)5.27
P/FCF Ratio-9.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$46.00Price Target Upside57.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$45.47M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low leverage and substantial equity provide durable financial flexibility for a clinical-stage biotech. Low interest burden preserves cash for R&D and trial funding, reducing solvency risk and allowing management to prioritize development timelines rather than short-term financing constraints.
Material Capital Raise Extends RunwayA ~$107M net equity raise materially extends runway and funds planned clinical development, reducing immediate refinancing risk. This durable increase in funding capacity gives the company time to execute Phase 2 starts and generate data before needing additional capital if burn is controlled.
Pipeline Expansion & Indication DiversificationBroadening ABI-6250 into cholestatic liver diseases and setting Phase 2 timelines diversifies program risk and targets high unmet need. Structural indication expansion increases potential market opportunity and strategic optionality, reducing reliance on a single asset if mid-stage data are positive.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow of roughly -$40M TTM translates losses into real cash outflows. Continued burn constrains runway, forces program prioritization or delays, and increases probability of further dilutive financing if clinical costs remain elevated over the next several quarters.
Volatile Revenue & Negative ProfitabilitySharp top-line decline and ongoing negative margins reflect reliance on irregular collaboration receipts and absence of product sales. This structural unpredictability limits internal funding capacity and complicates simultaneous advancement of multiple programs without external financing.
Reliance On Equity Financing / Dilution RiskThe company depends on capital markets to fund development, as shown by the recent sizable equity raise and enlarged warrant issuance. Persistent reliance on equity and expanded share reserves increases long-term dilution risk and can weaken per-share economics if additional raises are required.
Assembly Biosciences News
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $16.90 and its highest was $39.70 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is $531.30M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is Aug 12, 2026 which is in 24 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on May 07, 2026. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.65 by $0.11.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -0.72.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 19,817,250 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.65. Following the earnings report the stock price went down -3.847%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Currently, no hedge funds are holding shares in ASMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Assembly Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.00 (57.32% Upside)
$46.00 (57.32% Upside)
Hedge Fund Trend
Decreased
By 9.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $674.3 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.70%
12-Months-Change
Fundamentals
Return on Equity
-4.21%
Trailing 12-Months
Asset Growth
137.85%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
ASMB Stock 12 Month Forecast
Average Price Target
$46.00
▲(57.32% Upside)
Technical Analysis
Benitec Biopharma
―
Annexon Biosciences
―
Quantum-Si
―
Vor Biopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
27.13% Insiders
3.79% Mutual Funds
51.46% Other Institutional Investors
12.16% Public Companies and
Individual Investors